RxDoctor Payments Data

Larry Ryle, MD

Internal Medicine · Shepherdsville, KYNPI 1538295845

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 84 payments — averaging $12.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$354
  • AstraZeneca$227
  • Lilly USA, LLC$147
  • Amgen$141
  • GSK$69
  • Boehringer Ingelheim$35
  • plus $108 from 7 others

What the payments were for

  • Food & beverage$1,06098%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,082 in reported general payments places this provider in the 65th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$240,630
Medicare patients
1,025
Services billed
5,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin144$195,968
OzempicSemaglutide150$187,400
EliquisApixaban119$116,108
MounjaroTirzepatide87$97,291
TrulicityDulaglutide48$70,108
Tresiba Flextouch U-200Insulin Degludec26$34,428
RexultiBrexpiprazole16$34,269
XareltoRivaroxaban27$32,075
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,592
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$26,589
FarxigaDapagliflozin Propanediol18$24,921
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$24,595
NuedextaDextromethorphan Hbr/Quinidine13$20,105
JanuviaSitagliptin Phosphate12$19,678
Bydureon BciseExenatide Microspheres11$19,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat$35$213,605168 claims
Novo NordiskOzempic$354$187,400150 claims
Lilly USA, LLCMounjaro, Trulicity$147$167,399135 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$69$45,52977 claims
Otsuka America Pharmaceutical, Inc.Rexulti$14$34,26916 claims
Johnson & JohnsonXarelto$22$32,07527 claims
AstraZenecaFarxiga$227$24,92118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →